Genetic Testing Health: What Doctors and Genetic Counselors Say in 2026
Introduction: The Gap Between Getting a Genetic Test and Understanding What It Means
Imagine this scenario: a health-conscious individual receives results from a direct-to-consumer genetic test purchased online. The report flags an elevated risk for a serious hereditary condition. The immediate question becomes overwhelming: what does this actually mean, and what should happen next?
This scenario plays out millions of times each year across the United States. According to UT Southwestern researchers, genetic testing usage more than doubled from 19% to 40% between 2020 and 2022, with ancestry testing being the most popular entry point. The global genetic testing market is anticipated to reach USD 24.45 billion in 2025, with projections suggesting it could climb past USD 65 billion by 2034.
The central tension is clear: consumer genetic tests are widely accessible, but the gap between what they detect and what they mean clinically is enormous. Most people navigate that gap alone. This article brings together what doctors and genetic counselors actually say about direct-to-consumer tests, how to interpret results, when to seek clinical follow-up, and what data privacy risks now exist following the 23andMe bankruptcy.
Top Doctor Magazine has long served as a bridge between healthcare providers and patients, and this guide reflects that mission by translating complex medical perspectives into actionable guidance for health-conscious readers.
The DTC Genetic Testing Landscape in 2026: What Has Changed
Direct-to-consumer genetic testing refers to tests purchased without a physician’s order, processed by a private laboratory, and returned directly to the consumer. Dozens of companies now offer ancestry reports, health risk assessments, carrier status screening, and pharmacogenomic reports for prices ranging from under $50 to more than $2,000.
The most significant development in this space has been the 23andMe bankruptcy and acquisition. The company filed for Chapter 11 bankruptcy in March 2025 and was subsequently acquired by TTAM Research Institute for $305 million in July 2025. This raised urgent questions about what happens to the genetic data of over 15 million customers.
Twenty-eight states sought to block the data sale on genetic privacy grounds, highlighting a critical regulatory gap: HIPAA does not apply to direct-to-consumer companies like 23andMe. The federal health privacy law that protects medical records simply does not extend to consumer genetic data. As the New England Journal of Medicine noted in a perspective piece, the U.S. legal system currently relies on privacy policies to protect consumer genetic data while simultaneously treating that data as a valuable commercial asset.
This landscape makes physician and genetic counselor guidance more important than ever.
What Doctors Actually Think About DTC Genetic Tests
The physician perspective on direct-to-consumer genetic testing is nuanced. Approximately 70% of primary care physicians in a Duke University study believed genetic testing could help with early detection of adult-onset inherited diseases and incentivize patients to participate in their healthcare.
However, a confidence gap exists. Many physicians lacked confidence discussing results before undergoing genetic testing themselves; almost 60% felt more confident after personal testing experience. Compounding this issue, only about 30% of people who take direct-to-consumer tests share results with their healthcare providers.
Physicians express concern about false positives, false negatives, and patients making major health decisions based on incomplete data. The American College of Obstetricians and Gynecologists actively discourages use of direct-to-consumer tests for BRCA mutations because one popular test only checks for 3 mutations out of more than 500 BRCA mutations linked to cancer.
Labs processing direct-to-consumer genetic tests are not required to have FDA approval, unlike clinical genetic testing labs. The National Human Genome Research Institute advises doctors to refer patients to genetic counselors for high-risk variants, positive carrier results, or when family history suggests a genetic syndrome.
The professional consensus is clear: direct-to-consumer results are a starting point, not a diagnosis.
The BRCA Problem: Why DTC Tests Can Miss What Matters Most
BRCA testing represents the clearest and most consequential example of direct-to-consumer limitations. A peer-reviewed study in JCO Precision Oncology found that direct-to-consumer genetic testing misses more than 90% of BRCA1/2 pathogenic variants in individuals of non-Ashkenazi Jewish ancestry.
The same study found a 69% false-positive rate for non-Ashkenazi Jewish BRCA variants in direct-to-consumer results. Broader analysis shows that approximately 40% of variants found in direct-to-consumer raw data files are false positives overall.
This disparity exists because direct-to-consumer tests are calibrated primarily on Ashkenazi Jewish population data, making them far less reliable for people of other ethnic backgrounds. Non-white populations are systematically underserved by direct-to-consumer genetic testing accuracy.
The National Cancer Institute emphasizes that a positive BRCA result cannot indicate whether or when a person will develop cancer. Professional groups recommend enhanced screening protocols for confirmed BRCA carriers, but confirmation must come from clinical testing.
The physician takeaway: a negative direct-to-consumer BRCA result does not rule out hereditary cancer risk, especially for non-Ashkenazi individuals.
The Role of Genetic Counselors: What They Do and Why Patients Need One
A genetic counselor is a healthcare professional with specialized graduate training in medical genetics and counseling, certified by the American Board of Genetic Counseling. Their scope includes pre-test education, informed consent, result interpretation, psychosocial support, family communication guidance, and referral coordination.
The workforce reality presents challenges: fewer than 5,000 certified genetic counselors practice in the United States, a stark shortage relative to tens of millions of direct-to-consumer test users.
A 2021 survey found that 56.4% of genetic counselors feel negatively toward direct-to-consumer testing, yet 90.9% believe such testing would be improved with genetic counselor involvement. Only 31.2% of surveyed genetic counselors feel comfortable providing counseling to direct-to-consumer consumers, highlighting a significant workforce readiness gap.
A genetic counselor session typically includes personal and family health history review spanning three generations, risk assessment, discussion of testing options, result interpretation, and emotional support. Most health insurance plans cover genetic counseling when physician-referred, but direct-to-consumer-prompted counseling may require out-of-pocket payment.
When to See a Genetic Counselor vs. a Primary Care Doctor
Clear guidance helps patients understand which professional to contact and when.
Situations requiring a genetic counselor:
- Positive or high-risk direct-to-consumer result for hereditary cancer syndromes
- Strong family history of genetic conditions
- Abnormal prenatal screening results
- Carrier status findings
- Results suggesting rare inherited disorders
Situations where a primary care physician is the right first call:
- General questions about what a direct-to-consumer result means
- Deciding whether to pursue confirmatory clinical testing
- Pharmacogenomic results that may affect current medications
Primary care physicians can order confirmatory clinical genetic tests, interpret results in the context of a patient’s full medical history, and refer to genetic counselors or specialists as needed.
The CDC has observed that primary care providers are often the first approached with direct-to-consumer results because most consumers do not have immediate access to genetic counselors. Patients should bring their full direct-to-consumer report to any clinical appointment for context. Telehealth genetic counseling is a growing option that improves access, especially in underserved areas.
The Step-by-Step Journey: From DTC Result to Clinical Clarity
A practical roadmap helps patients respond appropriately to direct-to-consumer genetic test results.
Step 1: Emotional grounding. A direct-to-consumer result is a screening signal, not a diagnosis. Patients should avoid panic but not ignore concerning findings.
Step 2: Document and organize results. Downloading and saving the full report and raw data file is recommended. Patients should note which specific variants were flagged.
Step 3: Share results with a primary care physician. Scheduling an appointment specifically to discuss findings and asking whether confirmatory clinical testing is warranted is an important early step.
Step 4: Pursue confirmatory clinical genetic testing if indicated. Clinical labs follow FDA regulations and use more comprehensive panels.
Step 5: Request a genetic counselor referral for high-stakes results. This is especially important for hereditary cancer, cardiac conditions, or reproductive planning.
Step 6: Discuss family implications. Dr. Tuya Pal of Vanderbilt’s Inherited Cancer Registry emphasizes that inherited gene mutations are “a family condition.” Siblings and children each face a 50-50 risk once a mutation is identified.
Step 7: Develop an action plan with the care team. This may include enhanced screening schedules, lifestyle modifications, medication adjustments, or specialist referrals.
Pharmacogenomics: The Clinical Frontier Most DTC Tests Barely Touch
Pharmacogenomics studies how an individual’s genetic makeup affects their response to medications. Genetic variations in the CYP2D6 gene, for example, affect how the body metabolizes drugs like codeine and tamoxifen.
Clinical pharmacogenomics has grown rapidly in 2026. More clinics are integrating pharmacogenetic testing with clinical judgment, especially in psychiatry, cardiology, and oncology. A 2026 review described how pharmacogenomics enables a shift from trial-and-error prescriptions to predictive, genotype-directed treatment.
Most consumer genetic tests provide only surface-level pharmacogenomic data and lack the clinical context needed to guide actual prescribing decisions. If a direct-to-consumer test flags a pharmacogenomic variant, patients should discuss this with their prescribing physician before making any medication changes.
Clinical pharmacogenomic testing, ordered by a physician, can meaningfully inform treatment plans for patients on multiple medications or with complex psychiatric or cardiac histories.
Prenatal Genetic Testing: What the 2025 Guidelines Say
Prenatal direct-to-consumer testing and clinical prenatal genetic screening are not equivalent and should not be treated as interchangeable.
The Society for Maternal-Fetal Medicine released updated prenatal genetic screening guidelines in 2025, endorsed by ACOG. These guidelines emphasize that patients should receive pre-test counseling, understand their options, and have the right to choose, skip, or proceed directly to diagnostic testing.
Cell-free DNA screening is a clinical screening tool, not a diagnostic test. Non-reportable results warrant follow-up ultrasound, genetic counseling, and possibly diagnostic testing. Consumer ancestry or health tests should never substitute for clinical prenatal screening.
Genetic counselors are especially critical in the prenatal context, where results can carry profound emotional, ethical, and medical implications.
The Emotional Weight of Unexpected Genetic Findings
Genetic test results carry significant psychological weight that is often underestimated. A YouGov survey found that 65% of Americans said they would want genetic testing even if it meant learning they had a serious health risk. However, wanting to know and being emotionally prepared to process results are different things.
Common emotional responses include anxiety, denial, grief, relief, guilt regarding family implications, and decision paralysis. Direct-to-consumer tests sometimes surface variants the consumer was not looking for and had no preparation to receive.
Genetic counselors provide psychosocial support, helping patients process results emotionally, reframe risk in context, and make informed decisions without being driven by fear. If a direct-to-consumer result triggers significant anxiety, seeking support from a genetic counselor or mental health professional is appropriate and encouraged. Practicing self-care during this emotionally demanding process can also help patients maintain stability while navigating complex health decisions.
Data Privacy After 23andMe: What Patients Need to Know Now
The 23andMe bankruptcy and acquisition placed over 15 million customers’ genetic data in a precarious position. Twenty-eight states sought to block the sale on genetic privacy grounds, but the acquisition proceeded.
Direct-to-consumer companies are not covered entities under HIPAA. Genetic data sold to a new owner may be used for research, shared with third parties, or subject to different privacy policies than those in place when the consumer originally consented.
Before purchasing any direct-to-consumer genetic test, consumers should read the privacy policy carefully and understand who owns their data, how it may be used, and what happens if the company is sold or dissolved.
Existing 23andMe customers should consider downloading their data, reviewing privacy settings, and potentially deleting their account if they have concerns. As of 2026, federal legislation specifically protecting consumer genetic data remains incomplete.
Insurance, Coverage, and the Cost of Getting It Right
Direct-to-consumer genetic tests range from under $50 to more than $2,000 and are typically paid out-of-pocket. Most health insurance plans cover genetic testing when recommended by a physician, particularly for hereditary cancer risk assessment, carrier screening, and pharmacogenomics.
As of February 2026, Medicare does not cover genetic testing for individuals without a personal history of cancer.
A physician-ordered clinical genetic test is more likely to be covered by insurance, more comprehensive than a direct-to-consumer panel, and processed by a CLIA-certified, FDA-regulated laboratory. Before pursuing any genetic testing, consumers should call their insurance provider to understand coverage, prior authorization requirements, and documentation needs.
How to Find a Genetic Counselor and What to Expect
The access challenge is real: fewer than 5,000 certified genetic counselors practice in the United States. Resources include the National Society of Genetic Counselors directory and telehealth platforms offering certified genetic counseling.
A first appointment typically includes review of personal and family medical history spanning three generations, discussion of specific test results, risk assessment, explanation of testing options, and a written summary of findings and recommendations.
Genetic counselors focus on education, risk assessment, and psychosocial support. Medical geneticists are physicians who can diagnose and manage genetic conditions directly. Telehealth genetic counseling is expanding access to patients in rural or underserved areas.
Conclusion: Genetic Testing Is a Tool, the Medical Team Is the Guide
Direct-to-consumer genetic tests can be a valuable first step in understanding health, but they are not a substitute for clinical testing, physician interpretation, or genetic counseling. These tests miss the majority of BRCA variants in non-Ashkenazi populations, carry a significant false-positive rate, and are not regulated to the same standard as clinical labs.
Direct-to-consumer tests raise awareness, prompt conversations with physicians, and democratize access to genetic information when used as a starting point rather than an endpoint. The 23andMe bankruptcy serves as a reminder that genetic data is uniquely sensitive and permanent.
Genetic information, interpreted correctly in clinical context and with professional support, can genuinely transform health outcomes. The key is not to navigate it alone.
Take the Next Step: Connect With a Medical Professional Who Understands Genetic Health
Readers seeking qualified healthcare professionals can explore Top Doctor Magazine’s physician directory and nomination platform. Sharing this article with family members is particularly relevant given that inherited genetic variants are a family condition, with first-degree relatives facing a 50-50 risk.
Subscribing to the Top Doctor Magazine newsletter provides ongoing, physician-sourced guidance on genetic health, precision medicine, and emerging healthcare topics.
A concrete first action: before pursuing a direct-to-consumer test or after receiving results, patients should schedule a conversation with a primary care physician and ask whether a referral to a genetic counselor is appropriate. Learning how screening can help alleviate risk potentials from specialists who work with hereditary conditions can provide valuable perspective on what proactive testing and follow-up care can accomplish.
Readers with existing direct-to-consumer genetic test accounts should review their privacy settings and data-sharing preferences in light of recent industry changes. Those who have worked with a genetic counselor or physician who made a meaningful difference in their genetic health journey are encouraged to nominate that professional for a Top Doctor Magazine feature or award.
